Home Tags Biotech
The inside story of how the Silicon Valley burger startup Impossible Foods is going global after its sizzling Burger King debut
To create the Impossible Burger 2.0, the company had to change the recipe. One tweak that could be controversial involves using genetically modified soy.
Digital health startups worth $7.6 billion are set to IPO, breaking a 3-year drought. Here’s what 5 top VCs are keeping an eye on.
A new class of digital health companies could soon hit the public markets.
Dispensed: Troubles at uBiome, pharma giant Merck’s plan to upend the $20 billion HIV market, and why insurers are starting to embrace brands li...
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
The doctor who helped create a skin-care line for Amazon just started a new website to take on drug companies that charge $2,000 for common creams
Prescriptions to treat acne, burns, and growths can cost hundreds or even thousands of dollars. A new website will sell them for $24 to $60.
Doctors used a cutting-edge medical technique called gene therapy to treat 10 babies born with the disease. The biotech that helped saw its stock surge.
The IPO market has come storming back. Nasdaq’s head of healthcare listings gave us the lay of the land.
Nasdaq's head of healthcare listings, Jordan Saxe, weighed in on the state of healthcare IPOs at a hectic time for debuting on public markets.
Outrage over the cost of the life-saving drug insulin has drugmakers scrambling, but Congress and the public demand a price cut
Critics call the new programs "PR stunts,"and say drug companies should just lower their prices.
These powerful but little-known companies that have been blamed for high drug prices are now coming out of the shadows for a congressional interrogati...
The US has a high drug prices problem. These obscure but powerful companies will now face some tough questions on Capitol Hill.
The top scientist at AveXis told us the ‘unique’ strength that powered its $9 billion sale to Novartis, and it could shape the future of g...
Manufacturing has emerged as a huge challenge for the booming gene therapy industry because these products are so new and complex.
The deal has faced growing unhappiness from shareholders, who had been hoping for a different type of acquisition.